LCP Program
OtherThe LCP Program is continuous quality improvement program of end-of-life care implemented in hospice
NCT Number: NCT01470625
This is a before-after phase II study, according to the Medical Research Council framework, investigating the feasibility of introducing the Liverpool Care Pathway for the dying patient (LCP) in 5 Ligurian hospices.
Looking for future studies?
Notify MeAll sexes
Interventional
Phase 2
Hospice ASL 4, Chiavari, Genova, Italy
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The LCP Program is continuous quality improvement program of end-of-life care implemented in hospice
Time frame: 6 months after the end of LCP implementation
measured as proportion of hospices that complete the experimental phase of introducing the LCP Program and maintain the program in the 6 months subsequent the process of experimental LCP implementation
Time frame: 2-4 months after the patient's death
measured with the scale 1 (Informing and promoting shared decision making) from the Toolkit After-death bereaved family member interview (Teno 2001). The Toolkit will be administered to non-professional caregivers 2-4 months after the patient's death
Time frame: 2 - 4 months after the patient's death
measured with the scale 2 (Encouraging advance care planning) from the Toolkit After-death bereaved family member interview (Teno 2001). The Toolkit will be administered to non-professional caregivers 2-4 months after the patient's death
Time frame: 2 - 4 months after the patient's death
measured with the scale 3 (Focus on individual) from the Toolkit After-death bereaved family member interview (Teno 2001). The Toolkit will be administered to non-professional caregivers 2-4 months after the patient's death
Time frame: 2 - 4 months after the patient's death
measured with the scale 4 (Attending to the emotional and spiritual needs of the family) from the Toolkit After-death bereaved family member interview (Teno 2001). The Toolkit will be administered to non-professional caregivers 2-4 months after the patient's death
Time frame: 2 - 4 months after the patient's death
measured with the scale 5 (Providing coordination of care) from the Toolkit After-death bereaved family member interview (Teno 2001). The Toolkit will be administered to non-professional caregivers 2-4 months after the patient's death
Time frame: 2 - 4 months after the death of the patient
measured with the scale 6 (Supporting the self-efficacy of the family) from the Toolkit After-death bereaved family member interview (Teno 2001). The Toolkit will be administered to non-professional caregivers 2-4 months after the patient's death
Time frame: the last 3 days of life
measured with a specific tool in which all diagnostic and therapeutic procedures and drugs administered to the patient during the last 3 days of life are reported
Time frame: 2 - 4 months after the death of the patient
measured with the scale 7 (Overall quality of care provided to patients and family) from the Toolkit After-death bereaved family member interview (Teno 2001). The Toolkit will be administered to non-professional caregivers 2-4 months after the patient's death
Time frame: an expected average of 2 months after the patient's death
measured with a telephonic interview
Regional Palliative Care Network
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05089032
COVID-19, COVID-19 Pandemic
Brno, Czechia
View Trial DetailsNCT04966260
Death, End-Of-Life
Toronto, Ontario, Canada
View Trial DetailsNCT03856463
Cancer, Death
Stanford, California, United States
View Trial DetailsNCT05454644
Death, Deprescriptions
Donostia / San Sebastian, Gipuzkoa, Spain
View Trial Details